Phosphorylated Amyloid-beta (Abeta) was identified in Alzheimer's disease (AD) brain. Using an anti-sense peptide approach the human cyclin-dependent kinase-1 (CDK-1) was identified as being responsible for Abeta phosphorylation. The phosphorylated Abeta peptide showed increased neurotoxicity and reduced ability to form Congo red-positive fibrils. Mutation of the serine 26 residue and inhibition of Abeta phosphorylation by the CDK-1 inhibitor olomoucine prevented Abeta toxicity, suggesting that the phosphorylated Abeta peptide represents a toxic intermediate. Cannabinoids prevented phosphorylated Abeta toxicity.
The results from this study suggest that Abeta phosphorylation could play a role in AD pathology and represent a novel therapeutic target.
- Alzheimer Disease/pathology
- Amyloid beta-Peptides/metabolism
- Cyclin-Dependent Kinases/antagonists & inhibitors
- Enzyme Inhibitors/therapeutic use
- Nerve Degeneration/pathology
- Phosphoproteins/antagonists & inhibitors
- Purines/therapeutic use